TAAR1 and laryngotracheoesophageal cleft: It is also proposed that Tα1’s anti-tumor efficacy can be restored by blocking the MyD88 signaling pathway, raising the possibility that future research may examine ways to mitigate Tα1’s adverse effects when used to treat LC.